RecruitingNot ApplicableNCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Sponsor

Institut Claudius Regaud

Enrollment

450 participants

Start Date

Jul 23, 2025

Study Type

INTERVENTIONAL

Conditions

Urothelial Carcinoma Cervical Carcinoma Cutaneous Melanoma Renal Cancer Soft Tissue Sarcoma (STS)Prostate Adenocarcinoma Adenocarcinoma of Endometrium Nonseminomatous Germ Cell Tumor Seminomatous Germ Cell Tumor Upper Aerodigestive Tract Carcinoma

Summary

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

\. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
\. Age ≥ 18 years
\. Patient affiliated to a French Social Security scheme
\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion Criteria4

\. Patient with localized disease.
\. Pregnant or breast-feeding women.
\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Interventions

OTHERFor each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Locations(1)

Oncopole Claudius Regaud, IUCT-O

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06967961

Related Trials

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

NCT060228225 locations

64Cu-GRIP B in Patients With Advanced Malignancies

NCT058885321 location

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT049774538 locations

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT070253691 location

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT056166501 location